Provided by Tiger Trade Technology Pte. Ltd.

Aura Biosciences, Inc.

7.90
+0.10001.28%
Post-market: 7.900.00000.00%19:30 EDT
Volume:843.83K
Turnover:6.59M
Market Cap:816.75M
PE:-4.46
High:8.00
Open:7.80
Low:7.60
Close:7.80
52wk High:9.54
52wk Low:4.73
Shares:103.39M
Float Shares:79.92M
Volume Ratio:0.62
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7726
EPS(LYR):-1.7599
ROE:-53.49%
ROA:-31.24%
PB:2.59
PE(LYR):-4.49

Loading ...

Matrix Capital Management reports disposal of 6,922,870 Aura Biosciences shares for $39.05 million

Reuters
·
May 12

Aura Biosciences Q1 net loss widens to $33.7 million

Reuters
·
May 12

BRIEF-Aura Biosciences Q1 Operating Expenses USD 34.866 Million

Reuters
·
May 12

Press Release: Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights

Dow Jones
·
May 12

Aura Biosciences CEO Natalie Holles files initial beneficial ownership statement

Reuters
·
May 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 07

Aura Biosciences Completes Major Underwritten Equity Financing

TIPRANKS
·
May 06

Press Release: Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Dow Jones
·
May 06

Aura Biosciences Announces Stock Repurchase Agreement with Shareholder

TIPRANKS
·
May 05

Aura Biosciences repurchases Matrix stake for USD 39.04 million at USD 5.64/share

Reuters
·
May 05

Aura Biosciences $260M Spot Secondary priced at $6.00

TIPRANKS
·
May 04

Aura Biosciences Inc - Offering Price Set at $6.00 per Share and $5.99999 per Pre-Funded Warrant

THOMSON REUTERS
·
May 04

Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
May 04

Aura Biosciences launches underwritten public stock offering with pre-funded warrants

Reuters
·
May 04

Aura Biosciences names Natalie Holles CEO, replacing founder Elisabet de los Pinos

Reuters
·
May 04

Aura Biosciences Inc - Expects Phase 3 Compass Trial Enrollment Completion by Mid-2026 and Topline Data in Second Half of 2027

THOMSON REUTERS
·
May 04

Aura Biosciences Inc - Elisabet De Los Pinos Steps Down as CEO, President, and Board Member on April 30, 2026

THOMSON REUTERS
·
May 04

Press Release: Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion

Dow Jones
·
May 04

Aura Biosciences Inc (AURA) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Apr 29

Aura Biosciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 29